| Just Answers |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Finance > Taxes > Know Your Strategy When Adding Real Estate To Your Portfolio |
|
Just Answers - Know Your Strategy When Adding Real Estate To Your Portfolio
Are you thinking of adding real estate to your portfolio? If you are, please consider the acquisition of a prope According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product rty that could be a principal residence at a later time for you and your spouse. If you have always wanted to li ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in ve at the beach or in the mountains, this strategy allows you to get a second home or rental into your portfolio lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. while keeping the option open for making it a principal residence at a later date. Why is this important? Please here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe read on to find the answer. If we create a real estate piece to our portfolio that allow us to claim property d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro s our principal residence at some point, there is the potential to save on income taxes. Suppose that one purcha ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc ses a property as a rental with the idea that it would make an ideal principal residence at some later date. Ass easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi ming that they currently own a principal residence. they will be able to sell their current home and get the $25 nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically 0,000 or $500,000 gain exclusion (under IRC code 121) providing they meet the requirements. Later, they can move and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ into their one-time rental or second home and claim this as a principal residence (having it qualify as a princi ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi pal residence will require living in it for 2 out of 5 years). This would allow for the property owner to enjoy ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a increases in market values while enjoying favorable income tax attributes as well. This is called having the bes dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod of all possible worlds. In short, planning ahead will always save you money, especially if you are aware of th cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin e rules. ONe can even do a section 1031 exchange into a investment or business use property with the idea that i tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen will become a principal residence at some later date. The 1031 exchange is like-kind property allowing the defe t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel rral of gain when acquiring a substantially similar property to the one being sold. Imagine the tax savings when ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust this gain deferral becomes permanent when the property becomes a principal residence at a later point in time. I y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products wish you happy planning and invite you to ask questions or listen to my radio program, "Better Business", Satur . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de ay mornings at 10ET on WBIS AM 1190 (www.wbis1190.com). Ron Piner, CPA Host of "Better Business" Satu elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip rday Mornings at 10ET ON WBIS AM 1190 ww.wwbis1190.com www.mwibonline.com taxguy9@hotmail.co tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Naming and Branding Your Business List-Building | Dos and Don'ts The Truth Behind Tenancy Deposit Protection
|